Navigation Links
Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
Date:12/6/2007

CORONA, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis") on outstanding patent litigation related to Watson's generic version of Exelon(R) (rivastigmine tartrate) capsules.

Under the terms of the settlement agreement, Novartis has granted Watson a license to its U.S. patents covering Exelon(R) for a generic version of Exelon(R). The agreement generally provides that Watson will not commence marketing its generic equivalent product until sometime prior to the expiration of the patents covering Exelon(R). The specific date on which Watson may launch its generic product and other details concerning the settlement have not been disclosed. Watson's Abbreviated New Drug Application for its generic version of Exelon(R) has been tentatively approved by the U.S. Food and Drug Administration.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of litigation; risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities, including the U.S. Department of Justice and /or the Federal Trade Commission; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

Exelon(R) is a registered trademark of Novartis AG Corporation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
7. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
8. Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
9. Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
10. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
11. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a trusted name in ... trial program for all of the company’s desktop riser products. A simple application ... experience. , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Spain , Dec. 2, 2016 In ... natural sources apart from those derived from C. sativa, ... the Universita` di Napoli Federico II , the ... created the first comprehensive, critical, integrated and unified inventory ... The article focuses on the remarkable chemical and ...
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: